You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

437 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Nov 2024
Drug
Other Name(s): Kimmtrak®
Dec 1969
Drug
Other Name(s): Imjudo®
Dec 1969
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Document
Document
Dec 1969
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
In October 2024, the Ontario Breast Screening Program lowered the starting age for screening from age 50 to age 40.This page provides breast cancer...

Pages